Key result
Systemic cancer treatments induce thrombosis via coagulation activation, endothelial damage, dying tumor cells, and inflammation.
Why the study?
The specific mechanisms by which systemic cancer therapies cause arterial and venous thrombosis remain poorly understood, particularly immunothrombosis in solid tumors.
Population
Patients with solid tumors receiving systemic cancer treatment
Comparison
Various systemic cancer treatments including chemotherapy, antibody-based treatments, immunotherapy, and hormone receptor modulators
Design
Narrative review
Authors
Loading...
No immediate change to thromboprophylaxis warranted; leaves open biomarker-guided strategies in treated cancer patients.
Understanding the mechanisms of anticancer treatment-induced thrombosis is essential for identifying predictive biomarkers to guide effective thromboprophylaxis.
Albasanz-García et al. (2025) conducted a review in Cancer-associated thrombosis. Systemic cancer treatment was evaluated on Pathogenesis of thrombotic effects. Systemic cancer treatments induce thrombosis through mechanisms including coagulation activation, vascular endothelial damage, procoagulant effects from dying tumor cells, and inflammatory mediators.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: